Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145355 | 0.91 | KDM4C (0.43) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL15560839 | 0.83 | MEN1 (0.55) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL377967 | 0.81 | KDM4C (0.44) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL378049 | 0.79 | KMT2A (0.43) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL6202374 | 0.76 | KDM4C (0.46) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL14387001 | 0.75 | KDM4C (0.52) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL15652216 | 0.75 | MEN1 (0.50) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL145903 | 0.75 | KDM4C (0.44) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL1800634 | 0.75 | KDM4C (0.51) | KDM4CL3MBTL1RAB9ANPC1MEN1 | |
| SCHEMBL20847152 | 0.73 | HPGD (0.41) | KDM4CL3MBTL1RAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | KDM4C 4213/4885L3MBTL1 4277/4885RAB9A 3302/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4C 3902/4885L3MBTL1 4290/4885RAB9A 3059/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | KDM4C 396/4885L3MBTL1 659/4885RAB9A 2751/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | KDM4C 4213/4885L3MBTL1 4277/4885RAB9A 3302/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4C 4213/4885L3MBTL1 4277/4885RAB9A 3302/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | KDM4C 4213/4885L3MBTL1 4277/4885RAB9A 3302/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4C 3902/4885L3MBTL1 4290/4885RAB9A 3059/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4C 3902/4885L3MBTL1 4290/4885RAB9A 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.